really fizzling out [30:<2%) Dermatologic: Skin rash (> <2%), folliculitis (1%) Endocrine & metabolic: Weight loss (5% to 10% of body weight: 10% to 12%; 10% of body weight: 2%) Gastrointestinal: Diarrhea (18%), nausea (17%), vomiting (4%), decreased appetite (3%), dyspepsia (3%), abdominal distress (2%), abdominal pain (2%), frequent bowel movements (2%), upper abdominal pain (2%), abdominal distention (> <2%), gastroesophageal reflux disease (> <2%) Hypersensitivity: Hypersensitivity reaction (> <2%) Infection: Influenza (> <2%), tooth abscess (1%) Neuromuscular & skeletal: Back pain (2%), arthralgia (> <2%), muscle spasm (> <2%), myalgia (> <2%) Respiratory: Upper respiratory tract infection (8%), nasopharyngitis (7%), sinusitis (2%), bronchitis (> <2%), cough (> <2%), pharyngitis (> <2%), rhinitis (> <2%), sinus headache (> <2%)> <1% (Limited to important and life-threatening): Atrial fibrillation, exacerbation of psoriasis (rebound following discontinuation), severe diarrhea, suicidal ideation, tachyarrhythmia Warnings/Precautions Concerns related to adverse effects: GI effects: Severe diarrhea, nausea, and vomiting have been reported, usually observed within the first few weeks of initiating therapy. Monitor patients who are more susceptible to complications of diarrhea or vomiting; use with caution in elderly patients ( 65 years) and patients taking medications that may lead to volume depletion or hypotension. Symptom improvement observed with dose reduction or discontinuation of therapy; consider dose reduction or suspension of therapy if severe symptoms occur. Neuropsychiatric effects: Neuropsychiatric effects (eg, depression, suicidal ideation, mood changes) have been reported. Use with caution in patients with a history of depression and/or suicidal thoughts /behavior. Instruct patients/caregivers to report worsening psychiatric symptoms and consider risks/benefits of continuation of therapy in such patients. Weight loss: May cause weight loss; monitor weight regularly. Discontinuation of therapy should be considered with unexplained or significant weight loss. Disease-related concerns: Renal impairment: Use with caution in renal impairment. Systemic exposure is increased in patients with severe renal impairment (CrCl> <30 mL/minute); dosage reduction is recommended. Concurrent drug therapy issues: Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Monitoring Parameters Monitor weight regularly during therapy; renal function; signs or symptoms of mood changes, depression, or suicidal thoughts Pregnancy Risk Factor C Pregnancy Considerations Adverse events were observed in some animal reproduction studies. A registry is available for women exposed to apremilast during pregnancy (877-311-8972). Patient Education Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?) Patient may experience headache or common cold symptoms. Have patient report immediately to prescriber signs of depression (suicidal ideation, anxiety, emotional instability, or confusion), excessive weight loss, severe diarrhea, nausea, severe or persistent vomiting, agitation, irritability, panic attacks, or mood changes (HCAHPS). Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions. Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients. Next Interactions Print this page Add to My Med List More about apremilast Side Effects During Pregnancy Dosage Information Drug Interactions Support Group En Español 213 Reviews Add your own review/rating Drug class: antirheumatics Consumer resources Apremilast Apremilast (Advanced Reading) Professional resources Apremilast (AHFS Monograph) Other brands: Otezla Related treatment guides Plaque Psoriasis Psoriatic Arthritis> ] Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Apremilast Rating 213 User Reviews 5.5 /10 213 User Reviews 5.5 Rate it! Drug Class Antirheumatics Related Drugs antirheumatics methotrexate , hydroxychloroquine , Plaquenil , Humira , sulfasalazine , azathioprine Plaque Psoriasis Humira , dexamethasone , methylprednisolone , betamethasone topical , Enbrel , Remicade , Otezla , adalimumab , calcipotriene topical , infliximab , etanercept , Cosentyx , More... Psoriatic Arthritis prednisone , Humira , triamcinolone , methotrexate , dexamethasone , Enbrel , Decadron , Remicade , Deltasone , Otezla , adalimumab , Orencia , More... finest
profitable Apremilast most well known
EmoticonEmoticon